Mechano growth factor sits in a legal gray zone rather than a settled category. It is a splice variant of insulin-like growth factor 1, frequently sold in pegylated form as PEG-MGF, and it holds no approved human status under any major regulatory framework. The honest bottom line is that it is unapproved as a drug, ineligible as a dietary supplement, banned in sport, and available only under research-use-only labeling that carries buyer-side legal and health risk which turns heavily on where the buyer lives.
MGF is an unapproved new drug in the United States, cannot be sold as a dietary supplement, and is prohibited at all times in WADA-tested sport.
Research-use-only labeling, usually paired with a not-for-human-consumption warning, is a legal disclaimer that positions a substance as a laboratory reagent rather than a therapeutic product. Its function is defensive, not permissive: it grants no approved or cleared status and does not turn the peptide into a legal drug or supplement. Regulators weigh the totality of how a product is marketed, so the disclaimer carries little weight when the same seller advertises dosing, injection guidance, or performance benefits.
| Criteria | Legitimate research reagent | Consumer-facing MGF vial |
|---|---|---|
| Typical buyer | Institutional laboratory | Individual purchaser |
| Marketing claims | No dosing or benefit claims | Dosing, injection, or performance claims |
| Regulatory reading | Genuine research reagent | Unapproved new drug in commerce |
Research-use-only labeling is a liability disclaimer that grants no approved status, and regulators can still deem a consumer-facing MGF vial an unapproved new drug when the seller advertises dosing or performance claims.
MGF fails the statutory test for a dietary supplement on more than one independent ground, so the supplement pathway is closed rather than just difficult. The law recognizes only specific dietary-ingredient categories, and a synthetic pegylated growth-factor peptide is none of them. Route of administration settles it as well, since a supplement must be intended for ingestion while MGF is designed to be injected.
MGF fails the dietary-supplement definition on multiple independent grounds, including its injectable route, so any product presenting it as a supplement is mislabeled rather than compliant.
In the anti-doping context MGF is prohibited at all times, meaning both in and out of competition, under the peptide hormones, growth factors, related substances, and mimetics section of the World Anti-Doping Agency Prohibited List. As a growth factor derived from insulin-like growth factor 1 signaling, it falls squarely within that family, and the list's catch-all language for substances with similar structure or biological effect sweeps in variants not named explicitly. A therapeutic use exemption is not a realistic route, since an exemption requires a diagnosed medical need met by an approved treatment, which an unapproved research peptide cannot satisfy.
The World Anti-Doping Agency prohibits MGF at all times as a growth factor, and a first offense typically carries a multi-year period of ineligibility plus disqualification of results.
A buyer's legal exposure runs along a spectrum that widens sharply from private possession toward distribution, and the gap between the two is often misread as a single tolerated zone. Simple personal possession of an unapproved injectable peptide often goes unprosecuted, but that reflects enforcement discretion rather than any legal right, and it can change the moment a shipment crosses a border.
Personal possession of MGF often goes unprosecuted, but importation contravenes drug-import rules and redistribution introduces a misbranded drug into commerce, a distinct violation that can carry civil or criminal penalties.
The likelihood of customs seizure is genuinely uncertain, best described as variable rather than negligible or guaranteed, because border screening samples only a fraction of the small parcels moving internationally. Enforcement feels inconsistent because it is probabilistic and resource-limited: one order arrives untouched while an identical order weeks later is seized, not because the law changed but because inspection layers a screening lottery on top of risk-based targeting.
Customs seizure of MGF is probabilistic rather than certain, and a parcel identified as an unapproved drug is typically detained, refused entry, and destroyed with only a notice of detention sent to the recipient.
Legal treatment of MGF is not uniform: the same substance can be an unapproved research chemical in one country and a tightly scheduled prescription-only good in another. Easy online availability does not track legality, because research-chemical vendors ship into markets regardless of the destination country's rules. The only reliable read on the applicable rule comes from the specific medicines or therapeutic-goods authority of the buyer's own country.
| Criteria | United States | European Union | Australia |
|---|---|---|---|
| Classification | Unapproved new drug | Unauthorized medicine | Prescription-only or controlled good |
| Personal import | Enforcement policy, not a right | Varies by member state | Prohibited without authorization |
| Main pressure | Marketing and importation | National medicines enforcement | Restrictive, with meaningful penalties |
MGF is an unapproved new drug in the United States, an unauthorized medicine in the European Union, and a prescription-only or controlled good in strict-framework countries such as Australia, so legality turns on the buyer's national authority rather than on a seller's willingness to ship.
Availability and legality are separate questions, and treating them as one is the single most common error buyers make with substances like MGF. A product being purchasable proves only that a seller is willing to ship it, not that any authority has approved it or that use is lawful where the buyer lives. Research-chemical channels exist precisely to operate around the approval framework, using research-use-only disclaimers and offshore fulfillment to keep selling while sidestepping drug-marketing rules.
A product's easy availability reflects the limits of enforcement, not a grant of legitimacy, and MGF's lack of approval combined with its not-for-human-consumption labeling points away from lawful use rather than toward it.
Educational use only. This article describes what the published scientific and clinical literature reports about MGF. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
